Smoking reprograms immune cells into drivers of the inflammation they should prevent
For generations, the link between smoking and heart disease has been understood in broad strokes — but science has now traced the precise molecular path by which a cigarette becomes a cardiovascular catastrophe. Researchers at the University of Oklahoma have discovered that tobacco chemicals do not merely damage the lungs; they reprogram the immune system's own defenders into agents of chronic arterial inflammation. This finding reframes heart disease not only as a problem of cholesterol, but as a story of immunity turned against itself — and opens a door toward therapies that might one day protect those whom current treatments cannot fully reach.
- Smoking hijacks neutrophils — the body's most abundant immune defenders — transforming them into triggers of the very inflammation that destroys arteries over time.
- When these reprogrammed neutrophils die near macrophages, they release inflammatory proteins that cripple the macrophages' ability to clear cholesterol, allowing arterial plaque to accumulate unchecked.
- A startling discovery upended assumptions: tobacco chemicals administered orally produced the same immune cascade, meaning cardiovascular damage is systemic — not merely a consequence of lung inflammation.
- Current treatments target cholesterol but leave chronic inflammation largely unaddressed, exposing millions of smokers and former smokers to a parallel and equally lethal disease driver.
- The research team is now working to identify which of tobacco's 7,000-plus compounds cause the most harm and whether vaping or nicotine pouches trigger the same immune reprogramming — moving steadily toward human trials and potential new therapies.
Scientists at the University of Oklahoma have traced, in molecular detail, the chain reaction by which cigarette smoke accelerates heart disease — and the culprit, it turns out, is the immune system itself. Published in Circulation Research, the study reveals how tobacco chemicals activate neutrophils, the body's frontline white blood cells, causing them to multiply and flood the bloodstream in ways their biology was never designed to handle.
The damage unfolds in a cascade. These activated neutrophils encounter macrophages — immune cells responsible for clearing cholesterol and cellular debris — and die in their presence, releasing inflammatory proteins called Interleukin-1 alpha and Interleukin-1 beta. Those proteins disable the macrophages, leaving arterial walls chronically inflamed and allowing plaque to build without restraint. When that plaque destabilizes, the result can be a heart attack or stroke. Senior author Prabhakara Nagareddy described it starkly: smoking converts the immune system's first responders from protectors into accelerants of cardiovascular destruction.
Perhaps the most unexpected finding was that inhalation is not required. When tobacco compounds were administered orally in mouse models, they triggered the same immune cascade — suggesting that once these chemicals enter the bloodstream by any route, they can reprogram immune cells throughout the body. The cardiovascular threat is systemic, not simply a downstream effect of lung damage.
Nagareddy was careful to affirm that cholesterol-lowering treatments remain essential, but argued the new research illuminates what he calls the other half of the story: inflammation as an equally powerful and underaddressed driver of heart disease. The team's next steps include identifying which specific tobacco compounds cause the most harm, testing whether vaping and nicotine pouches produce the same immune reprogramming, and eventually replicating the findings in human subjects. For now, not smoking remains the clearest path to protection — but for those who cannot quit, this emerging map of immune dysfunction offers a new target for the treatments that may one day follow.
Researchers at the University of Oklahoma have mapped out a biological chain reaction that explains, in molecular detail, why smokers face such dramatically elevated risk of heart attacks and strokes. The work, published in Circulation Research, traces a path from the moment smoke enters the lungs to the moment plaque ruptures inside an artery—and it reveals that the immune system itself becomes the accelerant.
The mechanism centers on neutrophils, the body's most abundant white blood cells, which normally function as frontline defenders against infection. When cigarette smoke reaches the lungs, its chemical constituents activate these cells in ways evolution never prepared them for. The neutrophils multiply rapidly and migrate into the bloodstream, where they encounter macrophages—another class of immune cell whose job is to clean up cellular debris and excess cholesterol. This encounter proves catastrophic. The neutrophils die in the presence of the macrophages, and as they break apart, they release inflammatory proteins, particularly Interleukin-1 alpha and Interleukin-1 beta.
Those proteins fundamentally alter how the macrophages behave. Stripped of their ability to function normally, the macrophages can no longer remove dead cells or manage cholesterol buildup. The result is a chronically inflamed arterial wall where plaque accumulates unchecked. When that plaque destabilizes—especially in the presence of other risk factors like high blood pressure—it can dislodge, form a clot, and trigger a heart attack or stroke. Prabhakara Nagareddy, the senior author and a professor of medicine at the OU College of Medicine, described it plainly: smoking essentially hijacks the immune system's first responders, converting them from protectors into drivers of the very inflammation that damages the cardiovascular system.
What surprised the research team was the discovery that tobacco's inflammatory effects don't require inhalation. When the same chemicals were administered orally in their mouse model, they still activated the immune cascade. This finding suggests that once tobacco compounds enter the bloodstream—whether through the lungs or the digestive tract—they can directly reprogram immune cells throughout the body. The cardiovascular damage, in other words, is not confined to inflammation beginning in the lungs but extends to systemic immune dysfunction.
The current standard of care for cardiovascular disease focuses heavily on cholesterol reduction, and Nagareddy emphasized that this approach remains crucial. But the new research illuminates what he calls the other half of the story: chronic inflammation as a parallel and equally important driver of heart disease. Understanding which of the more than 7,000 chemical compounds in cigarette smoke trigger this inflammatory response could eventually lead to therapies that interrupt the process—protecting smokers and former smokers from some of the cardiovascular damage that cholesterol-lowering drugs alone cannot prevent.
The team's next steps are methodical. They plan to identify which specific tobacco compounds cause the most damage, then test whether other nicotine delivery systems—vaping, nicotine pouches—trigger the same immune cell reprogramming. They also intend to replicate their findings in human subjects, moving the work from the laboratory toward clinical application. For now, the message remains unchanged: not smoking, or quitting, remains the most effective intervention. But for those who cannot or will not quit, the emerging understanding of how smoke rewires immunity offers a new target for future treatment.
Citas Notables
Smoking essentially reprograms some of our 'first responder' immune cells. Instead of helping protect us, they become overactive and drive chronic inflammation inside the arteries.— Prabhakara Nagareddy, senior author and professor of medicine at OU College of Medicine
Most therapies today focus on lowering cholesterol. That's incredibly important, but inflammation is the other half of the story.— Prabhakara Nagareddy
La Conversación del Hearth Otra perspectiva de la historia
So the immune system is actually making the problem worse, not better?
Exactly. The neutrophils are doing what they're designed to do—responding to a threat. But cigarette smoke is a threat they've never encountered evolutionarily, so the response goes haywire. They multiply, they migrate, and when they die, they release inflammatory signals that cripple the macrophages that would normally be cleaning up the mess.
And the macrophages just... stop working?
They become dysfunctional. They can't remove dead cells or cholesterol anymore. So you get this accumulation in the arteries—plaque building up in an inflamed environment. That's the setup for a clot.
The oral administration finding is strange. Why would that matter?
It means the damage isn't just happening in your lungs. Once tobacco chemicals get into your bloodstream, they can reprogram immune cells anywhere in your body. The cardiovascular risk isn't just about lung inflammation spreading—it's systemic.
So quitting smoking would stop this process?
It would prevent new activation. But the researchers are thinking about people who can't or won't quit, or people who've already smoked. That's where understanding the inflammation pathway becomes therapeutic. If you can interrupt it with a drug, you might prevent some of the damage that cholesterol medications alone can't touch.
Is this the same for vaping?
That's what they're about to find out. The hypothesis is that if nicotine or other chemicals activate neutrophils the same way, you'd see the same cascade. But they don't know yet.